IDH1 and acute myeloid leukemia: Enasidenib, an IDH2 inhibitor, and ivosidenib, an IDH1 inhibitor, were approved in 2017 and 2019, respectively, for the treatment of patients with AML bearing IDH2 or IDH1 mutations.